Search Results - "de la Fuente, Oscar Lopez"

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL by Schmidl, Christian, Vladimer, Gregory I., Rendeiro, André F., Schnabl, Susanne, Krausgruber, Thomas, Taubert, Christina, Krall, Nikolaus, Pemovska, Tea, Araghi, Mohammad, Snijder, Berend, Hubmann, Rainer, Ringler, Anna, Runggatscher, Kathrin, Demirtas, Dita, de la Fuente, Oscar Lopez, Hilgarth, Martin, Skrabs, Cathrin, Porpaczy, Edit, Gruber, Michaela, Hoermann, Gregor, Kubicek, Stefan, Staber, Philipp B., Shehata, Medhat, Superti-Furga, Giulio, Jäger, Ulrich, Bock, Christoph

“…The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL). Although ibrutinib…”
Get full text

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study by Snijder, Berend, Vladimer, Gregory I, Krall, Nikolaus, Miura, Katsuhiro, Schmolke, Ann-Sofie, Kornauth, Christoph, Lopez de la Fuente, Oscar, Choi, Hye-Soo, van der Kouwe, Emiel, Gültekin, Sinan, Kazianka, Lukas, Bigenzahn, Johannes W, Hoermann, Gregor, Prutsch, Nicole, Merkel, Olaf, Ringler, Anna, Sabler, Monika, Jeryczynski, Georg, Mayerhoefer, Marius E, Simonitsch-Klupp, Ingrid, Ocko, Katharina, Felberbauer, Franz, Müllauer, Leonhard, Prager, Gerald W, Korkmaz, Belgin, Kenner, Lukas, Sperr, Wolfgang R, Kralovics, Robert, Gisslinger, Heinz, Valent, Peter, Kubicek, Stefan, Jäger, Ulrich, Staber, Philipp B, Superti-Furga, Giulio

“…Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies…”
Get full text

Global survey of the immunomodulatory potential of common drugs by Vladimer, Gregory I, Snijder, Berend, Krall, Nikolaus, Bigenzahn, Johannes W, Huber, Kilian V M, Lardeau, Charles-Hugues, Sanjiv, Kumar, Ringler, Anna, Berglund, Ulrika Warpman, Sabler, Monika, de la Fuente, Oscar Lopez, Knöbl, Paul, Kubicek, Stefan, Helleday, Thomas, Jäger, Ulrich, Superti-Furga, Giulio

“…A high-content screening platform that measures the immunological potential of small-molecule and biologic drugs by computationally determining changes in the…”
Get full text

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients by Vladimer, Gregory Ian, Schmidl, Christian, Renderio, Andre, Schnabl, Susanne, Pemovska, Tea, Snijder, Berend, Krausgruber, Thomas, Krall, Nikolaus, Araghi, Mohammad, Hubmann, Rainer, Ringler, Anna, Demirtas, Dita, Lopez de la Fuente, Oscar, Hilgrath, Martin, Skrabs, Cathrin, Porpaczy, Edit Anna, Gruber, Michaela, Hoermann, Gregor, Kubicek, Stefan, Staber, Philipp Bernhard, Shehata, Medhat M., Superti-Furga, Giulio, Bock, Christoph, Jaeger, Ulrich

“…▪ Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and accumulation of malignant B lymphocytes in the blood, bone marrow, spleen,…”
Get full text

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML by Pemovska, Tea, Vladimer, Gregory Ian, Sedlyarov, Vitaly, Hadzijusufovic, Emir, Gleixner, Karoline Veronika, Keller, Alexandra, Snijder, Berend, Krall, Nikolaus, Lopez de la Fuente, Oscar, Schneeweiss, Mathias A, Sperr, Wolfgang R., Knöbl, Paul, Geissler, Klaus, Staber, Philipp Bernhard, Jaeger, Ulrich, Valent, Peter, Superti Furga, Giulio

“…Chronic myelomonocytic leukemia (CMML) denotes a group of rare hematologic neoplasms characterized by peripheral blood monocytosis. Moreover, they have…”
Get full text

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies by Staber, Philipp Bernhard, Snijder, Berend, Vladimer, Gregory Ian, Krall, Nikolaus, Miura, Katsuhiro, Schmolke, Ann-Sofie, Kornauth, Christoph, Lopez de la Fuente, Oscar, Choi, Hye-Soo, van der Kouwe, Emiel, Kazianka, Lukas, Bigenzahn, Johannes, Hoermann, Gregor, Prutsch, Nicole, Merkel, Olaf, Ringler, Anna, Jeryczynski, Georg, Mayerhoefer, Marius, Simonitsch-Klupp, Ingrid, Felberbauer, Franz X, Muellauer, Leonhard, Prager, Gerald W, Korkmaz, Belgin, Kenner, Lukas, Sperr, Wolfgang R., Kralovics, Robert, Gisslinger, Heinz, Valent, Peter, Kubicek, Stefan, Jaeger, Ulrich, Superti-Furga, Giulio

“…Background. Patients with aggressive hematologic malignancies failing at least two lines of therapy are without further standard treatment options and have a…”
Get full text